marketcaparena
Search

    MLAB

    MESA LABORATORIES INC /CO/

    Company overview

    Market capitalization
    $744.19M
    Employees
    717
    Latest publication
    2026-09-29
    About MESA LABORATORIES INC /CO/

    Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment's products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ4 20262026-03-31 · USDQ3 20262025-12-31 · USDQ2 20262025-09-30 · USDQ1 20262025-06-30 · USDQ4 20252025-03-31 · USDQ3 20252024-12-31 · USDQ2 20252024-09-30 · USDQ1 20252024-06-30 · USD
    Total Revenue63,724,000USD65,126,000USD60,737,000USD59,543,000USD62,135,000USD62,840,000USD57,833,000USD58,170,000USD
    Cost Of Revenue17,074,000USD23,331,000USD23,406,000USD27,049,000USD23,723,000USD23,086,000USD22,378,000USD20,921,000USD
    Gross Profit46,650,000USD41,795,000USD37,331,000USD32,494,000USD38,412,000USD39,754,000USD35,455,000USD37,249,000USD
    Research Development5,247,000USD5,029,000USD5,048,000USD4,984,000USD5,096,000USD5,053,000USD4,634,000USD4,735,000USD
    Selling General Administrative24,132,000USD18,805,000USD17,763,000USD17,958,000USD20,579,000USD18,472,000USD17,464,000USD16,818,000USD
    Selling And Marketing Expenses10,078,000USD9,986,000USD9,796,000USD—11,268,000USD10,450,000USD9,849,000USD10,116,000USD
    Unclassified Operating Expenses4,445,000USD——6,488,000USD————
    Total Operating Expenses43,902,000USD33,820,000USD32,607,000USD29,430,000USD36,943,000USD33,975,000USD31,947,000USD31,669,000USD
    Operating Income2,748,000USD7,975,000USD4,724,000USD3,064,000USD1,469,000USD5,779,000USD3,508,000USD5,580,000USD
    Interest Expense2,596,000USD3,036,000USD2,862,000USD2,198,000USD2,519,000USD2,842,000USD3,018,000USD2,842,000USD
    Net Interest Income-2,596,000USD-3,036,000USD-2,862,000USD-2,198,000USD-2,519,000USD-2,842,000USD-3,018,000USD-2,842,000USD
    Income Before Tax-1,593,000USD4,596,000USD1,999,000USD7,012,000USD461,000USD-2,217,000USD3,812,000USD3,905,000USD
    Income Tax Expense2,543,000USD966,000USD-477,000USD2,270,000USD7,575,000USD-541,000USD384,000USD517,000USD
    Tax Provision2,543,000USD966,000USD-477,000USD2,270,000USD7,575,000USD-541,000USD384,000USD517,000USD
    Net Income-4,136,000USD3,630,000USD2,476,000USD4,742,000USD-7,114,000USD-1,676,000USD3,428,000USD3,388,000USD
    Net Income From Continuing Ops-4,136,000USD3,630,000USD2,476,000USD4,742,000USD-7,114,000USD-1,676,000USD3,428,000USD3,388,000USD
    Ebit-1,593,000USD7,632,000USD4,861,000USD9,210,000USD2,980,000USD625,000USD6,830,000USD6,747,000USD
    Ebitda4,157,000USD13,347,000USD10,710,000USD15,167,000USD10,477,000USD6,122,000USD12,898,000USD12,212,000USD
    Depreciation And Amortization5,750,000USD5,715,000USD5,849,000USD5,957,000USD7,497,000USD5,497,000USD6,068,000USD5,465,000USD
    Reconciled Depreciation5,750,000USD5,715,000USD5,849,000USD5,957,000USD7,497,000USD5,497,000USD6,068,000USD5,465,000USD
    Total Other Income Expense Net-4,341,000USD-3,379,000USD-2,725,000USD3,948,000USD-1,008,000USD-7,996,000USD304,000USD-1,675,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-03-31 · USDFY 20252025-03-31 · USDFY 20232023-03-31 · USDFY 20222022-03-31 · USDFY 20212021-03-31 · USDFY 20202020-03-31 · USDFY 20192019-03-31 · USDFY 20182018-03-31 · USD
    Total Revenue249,130,000USD240,978,000USD219,080,000USD184,335,000USD133,937,000USD117,687,000USD103,135,000USD96,179,000USD
    Cost Of Revenue90,860,000USD90,108,000USD85,387,000USD75,245,000USD46,923,000USD52,325,000USD42,219,000USD41,560,000USD
    Gross Profit158,270,000USD150,870,000USD133,693,000USD109,090,000USD87,014,000USD65,362,000USD60,916,000USD54,619,000USD
    Research Development20,308,000USD19,518,000USD20,490,000USD15,767,000USD10,388,000USD6,355,000USD3,506,000USD3,539,000USD
    Selling General Administrative78,658,000USD73,333,000USD72,444,000USD60,311,000USD45,788,000USD38,174,000USD31,295,000USD26,255,000USD
    Selling And Marketing Expenses40,793,000USD41,683,000USD37,439,000USD28,310,000USD18,480,000USD12,910,000USD8,260,000USD8,823,000USD
    Total Operating Expenses139,759,000USD134,534,000USD130,373,000USD104,388,000USD74,656,000USD57,439,000USD43,061,000USD38,617,000USD
    Operating Income18,511,000USD16,336,000USD3,320,000USD4,702,000USD12,358,000USD7,923,000USD9,781,000USD2,183,000USD
    Interest Expense10,692,000USD11,859,000USD4,770,000USD3,885,000USD8,023,999USD5,504,000USD0USD1,853,000USD
    Net Interest Income-10,692,000USD-11,859,000USD-4,770,000USD-3,885,000USD-7,917,000USD-4,544,000USD——
    Income Before Tax12,014,000USD5,961,000USD-389,000USD3,574,000USD2,303,000USD3,862,000USD8,623,000USD301,000USD
    Income Tax Expense5,302,000USD7,935,000USD-1,319,000USD1,703,000USD-971,000USD2,084,000USD1,139,000USD3,263,000USD
    Tax Provision5,302,000USD7,935,000USD-1,319,000USD1,703,000USD-971,000USD2,084,000USD1,139,000USD3,263,000USD
    Net Income6,712,000USD-1,974,000USD930,000USD1,871,000USD3,274,000USD1,778,000USD7,484,000USD-2,962,000USD
    Net Income From Continuing Ops6,712,000USD-1,974,000USD930,000USD1,871,000USD3,274,000USD1,349,000USD7,484,000USD-2,962,000USD
    Ebit12,014,000USD17,820,000USD4,381,000USD7,459,000USD10,327,000USD9,366,000USD25,929,000USD301,000USD
    Ebitda35,285,000USD42,347,000USD37,515,000USD32,527,000USD27,987,000USD22,356,000USD35,357,000USD9,772,000USD
    Depreciation And Amortization23,271,000USD24,527,000USD33,134,000USD25,068,000USD17,660,000USD12,990,000USD9,428,000USD9,471,000USD
    Reconciled Depreciation23,271,000USD24,527,000USD33,824,000USD25,068,000USD17,660,000USD12,990,000USD9,428,000USD9,471,000USD
    Total Other Income Expense Net-6,497,000USD-10,375,000USD-3,709,000USD-1,128,000USD-10,055,000USD-4,061,000USD-9,232,000USD-1,882,000USD
    Non Operating Income Net Other——1,061,000USD—-2,031,000USD1,443,000USD-1,158,000USD-1,882,000USD
    Net Income Applicable To Common Shares——930,000USD1,871,000USD3,274,000USD1,349,000USD7,484,000USD-2,962,000USD
    Interest Income————107,000USD960,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ4 20262026-03-31 · USDQ3 20262025-12-31 · USDQ2 20262025-09-30 · USDQ1 20262025-06-30 · USDQ4 20252025-03-31 · USDQ3 20252024-12-31 · USDQ2 20252024-09-30 · USDQ1 20252024-06-30 · USD
    Total Assets427,747,000USD434,849,000USD430,351,000USD435,743,000USD433,348,000USD437,148,000USD454,098,000USD440,361,000USD
    Intangible Assets83,347,000USD89,646,000USD93,268,000USD97,401,000USD96,875,000USD98,181,000USD108,823,000USD109,459,000USD
    Other Current Assets8,868,000USD9,865,000USD9,180,000USD9,805,000USD8,029,000USD13,120,000USD13,669,000USD10,883,000USD
    Total Liab241,502,000USD248,158,000USD251,883,000USD263,247,000USD273,518,000USD281,934,000USD292,647,000USD289,634,000USD
    Total Stockholder Equity186,245,000USD186,691,000USD178,468,000USD172,496,000USD159,830,000USD155,214,000USD161,451,000USD150,727,000USD
    Other Current Liab32,935,000USD25,537,000USD20,444,000USD11,009,000USD28,308,000USD23,912,000USD19,240,000USD18,822,000USD
    Common Stock375,348,000USD368,555,000USD365,173,000USD361,361,000USD358,541,000USD352,788,000USD349,529,000USD345,999,000USD
    Capital Stock375,348,000USD368,555,000USD365,173,000USD361,361,000USD358,541,000USD352,788,000USD349,529,000USD345,999,000USD
    Retained Earnings-185,747,000USD-180,727,000USD-183,473,000USD-185,067,000USD-188,936,000USD-180,952,000USD-178,407,000USD-180,969,000USD
    Good Will186,863,000USD189,303,000USD188,488,000USD188,050,000USD181,760,000USD177,152,000USD183,753,000USD179,722,000USD
    Cash26,928,000USD28,975,000USD20,422,000USD21,279,000USD27,321,000USD30,956,000USD24,337,000USD28,472,000USD
    Cash And Short Term Investments26,928,000USD28,975,000USD20,422,000USD21,279,000USD27,321,000USD30,956,000USD24,337,000USD28,472,000USD
    Total Current Assets106,268,000USD105,632,000USD97,433,000USD98,258,000USD102,685,000USD110,845,000USD107,978,000USD106,690,000USD
    Total Current Liabilities61,898,000USD54,395,000USD48,295,000USD149,494,000USD163,963,000USD155,878,000USD153,230,000USD54,865,000USD
    Current Deferred Revenue14,723,000USD14,558,000USD14,258,000USD15,077,000USD14,710,000USD14,608,000USD14,412,000USD14,634,000USD
    Net Debt128,241,000USD152,004,000USD170,008,000USD176,314,000USD154,151,000USD180,656,000USD198,518,000USD193,016,000USD
    Short Term Debt9,312,000USD9,047,000USD8,503,000USD105,403,000USD104,570,000USD104,448,000USD104,267,000USD6,690,000USD
    Short Long Term Debt5,625,000USD5,156,000USD4,688,000USD101,651,000USD101,047,000USD100,913,000USD100,779,000USD3,750,000USD
    Short Long Term Debt Total155,169,000USD180,979,000USD190,430,000USD197,593,000USD181,472,000USD211,612,000USD222,855,000USD221,488,000USD
    Long Term Debt145,857,000USD160,971,000USD170,164,000USD79,533,000USD76,902,000USD94,803,000USD104,203,000USD208,499,000USD
    Net Receivables44,099,000USD40,233,000USD40,092,000USD39,068,000USD41,970,000USD38,647,000USD40,234,000USD35,568,000USD
    Inventory26,373,000USD26,559,000USD27,739,000USD28,106,000USD25,365,000USD28,122,000USD29,738,000USD31,767,000USD
    Accounts Payable4,928,000USD5,253,000USD5,090,000USD6,270,000USD5,747,000USD4,087,000USD5,988,000USD5,659,000USD
    Property Plant Equipment Net30,613,000USD31,599,000USD31,835,000USD31,692,000USD32,333,000USD31,602,000USD32,073,000USD31,402,000USD
    Property Plant Equipment Gross60,728,000USD61,500,000USD60,612,000USD59,519,000USD58,754,000USD57,638,000USD57,729,000USD53,976,000USD
    Accumulated Other Comprehensive Income-3,356,000USD-1,137,000USD-3,232,000USD-3,798,000USD-9,775,000USD-16,622,000USD-9,671,000USD-14,303,000USD
    Common Stock Shares Outstanding5,544,000shares5,565,000shares5,535,000shares5,553,000shares5,429,000shares5,429,000shares5,471,000shares5,424,000shares
    Non Current Assets Total321,479,000USD329,217,000USD332,918,000USD337,485,000USD330,663,000USD326,303,000USD346,120,000USD333,671,000USD
    Non Current Liabilities Total179,604,000USD193,763,000USD203,588,000USD113,753,000USD109,555,000USD126,056,000USD139,417,000USD234,769,000USD
    Non Current Liabilities Other13,662,000USD———12,472,000USD92,000USD268,000USD282,000USD
    Non Currrent Assets Other19,155,000USD17,195,000USD17,855,000USD18,868,000USD18,324,000USD18,126,000USD20,142,000USD11,807,000USD
    Net Working Capital44,370,000USD51,237,000USD49,138,000USD-51,236,000USD-61,278,000USD-45,033,000USD-45,252,000USD51,825,000USD
    Unclassified Current Liabilities-5,625,000USD-5,156,000USD-4,688,000USD-89,916,000USD-90,419,000USD-92,090,000USD-91,456,000USD5,310,000USD
    Unclassified Non Current Liabilities20,085,000USD32,792,000USD33,424,000USD34,220,000USD20,181,000USD31,161,000USD34,946,000USD25,988,000USD
    Unclassified Equity-375,348,000USD-368,555,000USD-365,173,000USD-361,361,000USD-358,541,000USD-352,788,000USD-349,529,000USD-345,999,000USD
    Short Term Investments———1,732,000USD———1,514,000USD
    Unclassified Current Assets———-1,732,000USD———-1,514,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-03-31 · USDFY 20252025-03-31 · USDFY 20242024-03-31 · USDFY 20232023-03-31 · USDFY 20222022-03-31 · USDFY 20212021-03-31 · USDFY 20202020-03-31 · USDFY 20192019-03-31 · USD
    Total Assets427,747,000USD433,348,000USD446,796,000USD661,832,000USD707,369,000USD601,475,000USD420,206,000USD156,767,000USD
    Intangible Assets83,347,000USD96,875,000USD113,752,000USD18,226,000USD250,117,000USD111,741,000USD119,871,000USD33,219,000USD
    Other Current Assets8,868,000USD8,029,000USD9,408,000USD86,065,000USD18,284,000USD9,001,000USD6,050,000USD1,598,000USD
    Total Liab241,502,000USD273,518,000USD301,403,000USD268,352,000USD313,568,000USD195,248,000USD200,193,000USD45,456,000USD
    Total Stockholder Equity186,245,000USD159,830,000USD145,393,000USD393,480,000USD393,801,000USD406,227,000USD220,013,000USD111,311,000USD
    Other Current Liab32,935,000USD28,308,000USD18,192,000USD19,950,000USD14,845,000USD9,356,000USD8,667,000USD14,673,000USD
    Common Stock375,348,000USD358,541,000USD343,642,000USD332,076,000USD313,460,000USD317,652,000USD158,023,000USD39,823,000USD
    Capital Stock375,348,000USD358,541,000USD343,642,000USD332,076,000USD313,460,000USD317,652,000USD158,023,000USD39,823,000USD
    Retained Earnings-185,747,000USD-188,936,000USD-183,494,000USD74,199,000USD76,675,000USD72,459,000USD71,930,000USD73,303,000USD
    Good Will186,863,000USD181,760,000USD180,096,000USD286,444,000USD291,166,000USD160,841,000USD141,536,000USD66,377,000USD
    Cash26,928,000USD27,321,000USD28,214,000USD32,910,000USD49,346,000USD263,865,000USD81,380,000USD10,185,000USD
    Cash And Short Term Investments26,928,000USD27,321,000USD28,214,000USD32,910,000USD49,346,000USD263,865,000USD81,380,000USD10,185,000USD
    Total Current Assets106,268,000USD102,685,000USD109,352,000USD118,975,000USD124,318,000USD303,749,000USD122,792,000USD33,623,000USD
    Total Current Liabilities61,898,000USD163,963,000USD44,312,000USD43,359,000USD48,055,000USD32,583,000USD26,008,000USD23,661,000USD
    Current Deferred Revenue14,723,000USD14,710,000USD15,478,000USD14,407,000USD14,581,000USD9,291,000USD6,814,000USD3,965,000USD
    Net Debt141,903,000USD154,151,000USD203,083,000USD137,362,000USD171,787,000USD-117,167,000USD59,993,000USD12,553,000USD
    Short Term Debt9,312,000USD104,570,000USD2,986,000USD2,868,000USD2,768,000USD1,023,000USD1,095,000USD2,125,000USD
    Short Long Term Debt5,625,000USD101,047,000USD—————2,125,000USD
    Short Long Term Debt Total168,831,000USD181,472,000USD231,297,000USD186,140,000USD221,133,000USD146,698,000USD141,373,000USD22,738,000USD
    Long Term Debt145,857,000USD76,902,000USD221,698,000USD183,272,000USD218,365,000USD145,675,000USD140,278,000USD20,613,000USD
    Net Receivables44,099,000USD41,970,000USD39,055,000USD42,551,000USD41,224,000USD23,787,000USD21,132,000USD12,516,000USD
    Inventory26,373,000USD25,365,000USD32,675,000USD34,642,000USD24,606,000USD11,178,000USD14,230,000USD6,772,000USD
    Accounts Payable4,928,000USD5,747,000USD6,041,000USD6,134,000USD7,897,000USD4,473,000USD3,408,000USD2,898,000USD
    Property Plant Equipment Net48,113,000USD32,333,000USD41,437,000USD28,149,000USD28,620,000USD21,998,000USD22,066,000USD22,225,000USD
    Property Plant Equipment Gross60,728,000USD58,754,000USD54,285,000USD47,917,000USD46,346,000USD21,998,000USD22,066,000USD22,225,000USD
    Accumulated Other Comprehensive Income-3,356,000USD-9,775,000USD-14,755,000USD-12,795,000USD3,666,000USD16,116,000USD-9,940,000USD-1,815,000USD
    Common Stock Shares Outstanding5,565,000shares5,429,000shares5,386,000shares5,361,000shares5,335,000shares5,124,000shares4,371,000shares4,033,000shares
    Non Current Assets Total321,479,000USD330,663,000USD337,444,000USD542,857,000USD583,051,000USD297,726,000USD297,414,000USD123,144,000USD
    Non Current Liabilities Total179,604,000USD109,555,000USD257,091,000USD224,993,000USD265,513,000USD162,665,000USD174,185,000USD21,795,000USD
    Non Current Liabilities Other13,662,000USD12,472,000USD15,613,000USD7,693,000USD7,924,000USD715,000USD1,358,000USD105,000USD
    Non Currrent Assets Other1,655,000USD18,324,000USD867,000USD208,962,000USD11,830,000USD2,530,000USD275,348,000USD246,000USD
    Net Working Capital44,370,000USD-61,278,000USD65,040,000USD75,616,000USD76,263,000USD271,166,000USD96,784,000USD9,962,000USD
    Unclassified Current Liabilities-5,625,000USD-90,419,000USD1,615,000USD—7,964,000USD8,440,000USD6,024,000USD-2,125,000USD
    Unclassified Non Current Liabilities20,085,000USD20,181,000USD19,780,000USD-35,969,000USD—-193,924,000USD-32,645,000USD—
    Unclassified Equity-375,348,000USD-358,541,000USD-343,642,000USD-332,076,000USD-313,460,000USD-317,652,000USD-158,023,000USD-39,823,000USD
    Other Assets——1USD2,756,000USD554,431,000USD275,144,000USD11,461,000USD1,323,000USD
    Deferred Long Term Liab———34,028,000USD—16,275,000USD32,549,000USD—
    Other Liab———35,969,000USD39,712,000USD193,924,000USD32,645,000USD1,182,000USD
    Net Tangible Assets———107,036,000USD393,801,000USD294,486,000USD-41,394,000USD44,934,000USD
    Unclassified Current Assets———-77,193,000USD-9,142,000USD-4,082,000USD—2,552,000USD
    Unclassified Non Current Assets————-553,113,000USD-274,528,000USD-272,868,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20262026-03-31 · USDFY 20252025-03-31 · USDFY 20242024-03-31 · USDFY 20232023-03-31 · USDFY 20222022-03-31 · USDFY 20212021-03-31 · USDFY 20202020-03-31 · USDFY 20192019-03-31 · USD
    Net Income6,712,000USD-1,974,000USD-254,246,000USD930,000USD1,871,000USD3,274,000USD1,349,000USD7,484,000USD
    Depreciation23,271,000USD24,527,000USD31,574,000USD33,824,000USD25,068,000USD17,660,000USD12,990,000USD9,428,000USD
    Stock Based Compensation17,868,000USD13,142,000USD11,936,000USD12,538,000USD11,391,000USD9,268,000USD5,525,000USD4,212,000USD
    Other Non Cash Items1,259,000USD4,281,000USD277,317,000USD1,297,000USD7,957,000USD5,122,000USD11,803,000USD4,011,000USD
    Change To Account Receivables-3,206,000USD-2,925,000USD4,940,000USD-2,121,000USD-6,752,000USD-647,000USD-1,665,000USD1,592,000USD
    Change To Inventory-4,434,000USD1,153,000USD2,563,000USD-10,182,000USD-1,045,000USD929,000USD414,000USD2,574,000USD
    Change In Working Capital-4,987,000USD6,904,000USD5,973,000USD-17,112,000USD-7,192,000USD5,252,000USD-3,137,000USD7,891,000USD
    Total Cash From Operating Activities42,831,000USD46,808,000USD44,133,000USD27,983,000USD39,223,000USD37,073,000USD26,559,000USD30,554,000USD
    Capital Expenditures-3,250,000USD-4,499,000USD-2,567,000USD-4,544,000USD-4,432,000USD-1,992,000USD-1,498,000USD-1,262,000USD
    Free Cash Flow39,581,000USD42,309,000USD41,566,000USD23,439,000USD34,791,000USD35,081,000USD25,061,000USD29,292,000USD
    Total Cashflows From Investing Activities-3,250,000USD-4,499,000USD-81,306,000USD-9,494,000USD-305,225,000USD-1,992,000USD-185,585,000USD-3,880,000USD
    Net Borrowings-26,749,000USD-42,346,000USD37,500,000USD-36,000,000USD49,000,000USD-664,000USD144,070,000USD-23,625,000USD
    Total Cash From Financing Activities-41,854,000USD-44,509,000USD32,836,000USD-33,328,000USD52,576,000USD146,228,000USD231,277,000USD-21,672,000USD
    Dividends Paid-3,523,000USD-3,468,000USD-3,447,000USD-3,406,000USD-3,339,000USD-3,165,000USD-2,722,000USD-2,462,000USD
    Change In Cash-393,000USD-893,000USD-4,696,000USD-16,436,000USD-214,519,000USD182,485,000USD71,195,000USD4,716,000USD
    Begin Period Cash Flow27,321,000USD28,214,000USD32,910,000USD49,346,000USD263,865,000USD81,380,000USD10,185,000USD5,469,000USD
    End Period Cash Flow26,928,000USD27,321,000USD28,214,000USD32,910,000USD49,346,000USD263,865,000USD81,380,000USD10,185,000USD
    Other Cashflows From Investing Activities-3,250,000USD-250,000USD—-4,950,000USD—-1,992,000USD-184,087,000USD-2,618,000USD
    Other Cashflows From Financing Activities-11,582,000USD1,305,000USD-1,217,000USD6,078,000USD76,915,000USD3,458,000USD-5,441,000USD6,415,000USD
    Unclassified Operating Cash Flow-1,292,000USD—-28,421,000USD-3,494,000USD—-3,503,000USD-1,971,000USD-2,472,000USD
    Unclassified Investing Cash Flow3,250,000USD4,749,000USD2,567,000USD9,494,000USD4,432,000USD3,984,000USD185,585,000USD3,880,000USD
    Investments—-4,499,000USD-81,306,000USD-9,494,000USD-305,225,000USD-1,992,000USD-185,585,000USD-3,880,000USD
    Sale Purchase Of Stock——-728,000USD6,997,000USD-875,000USD150,361,000USD177,445,000USD-5,095,000USD
    Change To Liabilities———-4,905,000USD3,956,000USD650,000USD-2,208,000USD6,569,000USD
    Issuance Of Capital Stock———0USD0USD145,935,000USD84,995,000USD—
    Cash And Cash Equivalents Changes———-14,839,000USD—181,309,000USD71,195,000USD4,716,000USD
    Unclassified Financing Cash Flow———-6,997,000USD-69,125,000USD-3,762,000USD-82,075,000USD3,095,000USD
    Exchange Rate Changes——————-1,056,000USD-286,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262025-12-31 · USDQ2 20262025-09-30 · USDQ1 20262025-06-30 · USDQ4 20252025-03-31 · USDQ3 20252024-12-31 · USDQ2 20252024-09-30 · USDQ1 20252024-06-30 · USDQ4 20242024-03-31 · USD
    Net Income3,630,000USD2,476,000USD4,742,000USD-7,114,000USD-1,676,000USD3,428,000USD3,388,000USD-254,583,000USD
    Depreciation5,715,000USD5,849,000USD5,957,000USD7,497,000USD5,497,000USD6,068,000USD5,465,000USD6,295,000USD
    Stock Based Compensation3,382,000USD3,812,000USD3,881,000USD3,138,000USD3,239,000USD3,837,000USD2,928,000USD2,792,000USD
    Other Non Cash Items-3,960,000USD1,533,000USD-4,736,000USD-542,000USD7,816,000USD-8,400,000USD-1,010,000USD249,818,000USD
    Change To Account Receivables-819,000USD-1,696,000USD3,436,000USD-3,016,000USD657,000USD-4,048,000USD3,482,000USD-3,354,000USD
    Change To Inventory596,000USD-766,000USD-3,290,000USD1,692,000USD-495,000USD627,000USD-671,000USD2,346,000USD
    Change In Working Capital9,987,000USD-5,448,000USD-7,951,000USD9,686,000USD3,563,000USD338,000USD-338,000USD8,561,000USD
    Total Cash From Operating Activities18,754,000USD8,222,000USD1,893,000USD12,665,000USD18,439,000USD5,271,000USD10,433,000USD12,883,000USD
    Capital Expenditures-732,000USD-1,092,000USD-1,009,000USD-1,007,000USD-813,000USD-1,788,000USD-891,000USD-535,000USD
    Free Cash Flow18,022,000USD7,130,000USD884,000USD11,658,000USD17,626,000USD3,483,000USD9,542,000USD12,348,000USD
    Total Cashflows From Investing Activities-732,000USD-1,092,000USD-1,009,000USD-1,007,000USD-813,000USD-1,788,000USD-891,000USD426,000USD
    Net Borrowings-8,687,000USD-6,437,000USD3,062,000USD-17,938,000USD-9,438,000USD-7,127,000USD——
    Total Cash From Financing Activities-9,785,000USD-7,883,000USD-8,427,000USD-16,193,000USD-10,597,000USD-8,610,000USD-9,109,000USD-12,933,000USD
    Dividends Paid-884,000USD-882,000USD-873,000USD-870,000USD-869,000USD-866,000USD-863,000USD-864,000USD
    Change In Cash8,553,000USD-857,000USD-6,042,000USD-3,635,000USD6,619,000USD-4,135,000USD258,000USD-10,000USD
    Begin Period Cash Flow20,422,000USD21,279,000USD27,321,000USD30,956,000USD24,337,000USD28,472,000USD28,214,000USD28,224,000USD
    End Period Cash Flow28,975,000USD20,422,000USD21,279,000USD27,321,000USD30,956,000USD24,337,000USD28,472,000USD28,214,000USD
    Other Cashflows From Financing Activities-214,000USD-564,000USD-10,616,000USD2,615,000USD20,000USD-307,000USD-1,023,000USD-569,000USD
    Investments—-1,092,000USD-1,009,000USD-1,007,000USD-813,000USD-1,788,000USD-891,000USD426,000USD
    Unclassified Investing Cash Flow—1,092,000USD1,009,000USD1,257,000USD—1,788,000USD——
    Other Cashflows From Investing Activities———-250,000USD————
    Unclassified Financing Cash Flow——————-7,223,000USD-12,216,000USD
    Sale Purchase Of Stock———————716,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    FY 2026Yearly · 2026-03-31GeographyChina20,449,000USD0000724004-26-000047
    FY 2026Yearly · 2026-03-31GeographyOther111,786,000USD0000724004-26-000047
    FY 2026Yearly · 2026-03-31GeographyUnited States116,895,000USD0000724004-26-000047
    Q4 2026Quarterly · 2026-03-31GeographyChina4,060,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31GeographyOther29,607,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31GeographyUnited States30,057,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31ProductConsumables40,061,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31ProductHardware And Software11,466,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31ProductServices12,197,000USDLegacy provider
    FY 2026Yearly · 2026-03-31ProductConsumables145,942,000USD0000724004-26-000047
    FY 2026Yearly · 2026-03-31ProductHardware And Software57,450,000USD0000724004-26-000047
    FY 2026Yearly · 2026-03-31ProductServices45,738,000USD0000724004-26-000047
    Q4 2026Quarterly · 2026-03-31SegmentBiopharmaceutical Development8,847,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31SegmentCalibration Solutions13,559,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31SegmentClinical Genomics12,182,000USDLegacy provider
    Q4 2026Quarterly · 2026-03-31SegmentSterilization And Disinfection Control29,136,000USDLegacy provider
    FY 2026Yearly · 2026-03-31SegmentBiopharmaceutical Development48,626,000USD0000724004-26-000047
    FY 2026Yearly · 2026-03-31SegmentCalibration Solutions53,551,000USD0000724004-26-000047
    FY 2026Yearly · 2026-03-31SegmentClinical Genomics45,386,000USD0000724004-26-000047
    FY 2026Yearly · 2026-03-31SegmentSterilization And Disinfection Control101,567,000USD0000724004-26-000047
    Q3 2026Quarterly · 2025-12-31GeographyChina5,645,000USD0000724004-26-000016
    Q3 2026Quarterly · 2025-12-31GeographyOther29,589,000USD0000724004-26-000016
    Q3 2026Quarterly · 2025-12-31GeographyUnited States29,892,000USD0000724004-26-000016
    Q3 2026Quarterly · 2025-12-31ProductConsumables36,731,000USD0000724004-26-000016
    Q3 2026Quarterly · 2025-12-31ProductHardware And Software17,344,000USD0000724004-26-000016
    Q3 2026Quarterly · 2025-12-31ProductServices11,051,000USD0000724004-26-000016
    Q3 2026Quarterly · 2025-12-31SegmentBiopharmaceutical Development14,373,000USD0000724004-26-000016
    Q3 2026Quarterly · 2025-12-31SegmentCalibration Solutions14,072,000USD0000724004-26-000016
    Q3 2026Quarterly · 2025-12-31SegmentClinical Genomics11,767,000USD0000724004-26-000016
    Q3 2026Quarterly · 2025-12-31SegmentSterilization And Disinfection Control24,914,000USD0000724004-26-000016
    Q2 2026Quarterly · 2025-09-30GeographyChina5,315,000USD0000724004-25-000013
    Q2 2026Quarterly · 2025-09-30GeographyOther26,122,000USD0000724004-25-000013
    Q2 2026Quarterly · 2025-09-30GeographyUnited States29,300,000USD0000724004-25-000013
    Q2 2026Quarterly · 2025-09-30ProductConsumables33,377,000USD0000724004-25-000013
    Q2 2026Quarterly · 2025-09-30ProductHardware And Software16,071,000USD0000724004-25-000013
    Q2 2026Quarterly · 2025-09-30ProductServices11,289,000USD0000724004-25-000013
    Q2 2026Quarterly · 2025-09-30SegmentBiopharmaceutical Development13,920,000USD0000724004-25-000013
    Q2 2026Quarterly · 2025-09-30SegmentCalibration Solutions13,570,000USD0000724004-25-000013
    Q2 2026Quarterly · 2025-09-30SegmentClinical Genomics11,140,000USD0000724004-25-000013
    Q2 2026Quarterly · 2025-09-30SegmentSterilization And Disinfection Control22,107,000USD0000724004-25-000013
    Q1 2026Quarterly · 2025-06-30GeographyChina5,429,000USD0001437749-25-024715
    Q1 2026Quarterly · 2025-06-30GeographyOther26,468,000USD0001437749-25-024715
    Q1 2026Quarterly · 2025-06-30GeographyUnited States27,646,000USD0001437749-25-024715
    Q1 2026Quarterly · 2025-06-30ProductConsumables35,773,000USD0001437749-25-024715
    Q1 2026Quarterly · 2025-06-30ProductHardware And Software12,569,000USD0001437749-25-024715
    Q1 2026Quarterly · 2025-06-30ProductServices11,201,000USD0001437749-25-024715
    Q1 2026Quarterly · 2025-06-30SegmentBiopharmaceutical Development11,486,000USD0001437749-25-024715
    Q1 2026Quarterly · 2025-06-30SegmentCalibration Solutions12,350,000USD0001437749-25-024715
    Q1 2026Quarterly · 2025-06-30SegmentClinical Genomics10,297,000USD0001437749-25-024715
    Q1 2026Quarterly · 2025-06-30SegmentSterilization And Disinfection Control25,410,000USD0001437749-25-024715
    FY 2025Yearly · 2025-03-31GeographyChina25,312,000USD0000724004-26-000047
    FY 2025Yearly · 2025-03-31GeographyOther99,051,000USD0000724004-26-000047
    FY 2025Yearly · 2025-03-31GeographyUnited States116,615,000USD0000724004-26-000047
    Q4 2025Quarterly · 2025-03-31GeographyChina5,041,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31GeographyOther25,894,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31GeographyUnited States31,200,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31ProductConsumables36,994,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31ProductHardware And Software14,179,000USDLegacy provider
    Q4 2025Quarterly · 2025-03-31ProductServices10,962,000USDLegacy provider
    FY 2025Yearly · 2025-03-31ProductConsumables138,734,000USD0000724004-26-000047
    FY 2025Yearly · 2025-03-31ProductHardware And Software59,661,000USD0000724004-26-000047
    FY 2025Yearly · 2025-03-31ProductServices42,583,000USD0000724004-26-000047
    Q3 2025Quarterly · 2024-12-31GeographyChina6,322,000USD0000724004-26-000016
    Q3 2025Quarterly · 2024-12-31GeographyOther26,042,000USD0000724004-26-000016
    Q3 2025Quarterly · 2024-12-31GeographyUnited States30,476,000USD0000724004-26-000016
    Q3 2025Quarterly · 2024-12-31ProductConsumables36,809,000USD0000724004-26-000016
    Q3 2025Quarterly · 2024-12-31ProductHardware And Software15,796,000USD0000724004-26-000016
    Q3 2025Quarterly · 2024-12-31ProductServices10,235,000USD0000724004-26-000016
    Q3 2025Quarterly · 2024-12-31SegmentBiopharmaceutical Development12,237,000USD0000724004-26-000016
    Q3 2025Quarterly · 2024-12-31SegmentCalibration Solutions14,429,000USD0000724004-26-000016
    Q3 2025Quarterly · 2024-12-31SegmentClinical Genomics12,667,000USD0000724004-26-000016
    Q3 2025Quarterly · 2024-12-31SegmentSterilization And Disinfection Control23,507,000USD0000724004-26-000016
    Q2 2025Quarterly · 2024-09-30GeographyChina7,390,000USD0000724004-25-000013
    Q2 2025Quarterly · 2024-09-30GeographyOther22,365,000USD0000724004-25-000013
    Q2 2025Quarterly · 2024-09-30GeographyUnited States28,078,000USD0000724004-25-000013
    Q2 2025Quarterly · 2024-09-30ProductConsumables31,921,000USD0000724004-25-000013
    Q2 2025Quarterly · 2024-09-30ProductHardware And Software15,611,000USD0000724004-25-000013
    Q2 2025Quarterly · 2024-09-30ProductServices10,301,000USD0000724004-25-000013
    Q2 2025Quarterly · 2024-09-30SegmentBiopharmaceutical Development11,867,000USD0000724004-25-000013
    Q2 2025Quarterly · 2024-09-30SegmentCalibration Solutions12,262,000USD0000724004-25-000013
    Q2 2025Quarterly · 2024-09-30SegmentClinical Genomics11,499,000USD0000724004-25-000013
    Q2 2025Quarterly · 2024-09-30SegmentSterilization And Disinfection Control22,205,000USD0000724004-25-000013
    Q1 2025Quarterly · 2024-06-30GeographyChina6,559,000USD0001437749-25-024715
    Q1 2025Quarterly · 2024-06-30GeographyOther24,750,000USD0001437749-25-024715
    Q1 2025Quarterly · 2024-06-30GeographyUnited States26,861,000USD0001437749-25-024715
    Q1 2025Quarterly · 2024-06-30ProductConsumables33,010,000USD0001437749-25-024715
    Q1 2025Quarterly · 2024-06-30ProductHardware And Software14,075,000USD0001437749-25-024715
    Q1 2025Quarterly · 2024-06-30ProductServices11,085,000USD0001437749-25-024715
    Q1 2025Quarterly · 2024-06-30SegmentBiopharmaceutical Development12,008,000USD0001437749-25-024715
    Q1 2025Quarterly · 2024-06-30SegmentCalibration Solutions11,801,000USD0001437749-25-024715
    Q1 2025Quarterly · 2024-06-30SegmentClinical Genomics11,404,000USD0001437749-25-024715
    Q1 2025Quarterly · 2024-06-30SegmentSterilization And Disinfection Control22,957,000USD0001437749-25-024715
    FY 2024Yearly · 2024-03-31GeographyChina24,933,000USD0000724004-26-000047
    FY 2024Yearly · 2024-03-31GeographyOther84,859,000USD0000724004-26-000047
    FY 2024Yearly · 2024-03-31GeographyUnited States106,395,000USD0000724004-26-000047
    FY 2024Yearly · 2024-03-31ProductConsumables120,976,000USD0000724004-26-000047
    FY 2024Yearly · 2024-03-31ProductHardware And Software55,820,000USD0000724004-26-000047
    FY 2024Yearly · 2024-03-31ProductServices39,391,000USD0000724004-26-000047
    Q4 2024Quarterly · 2024-03-31SegmentBiopharmaceutical Development12,186,000USDLegacy provider
    Q4 2024Quarterly · 2024-03-31SegmentCalibration Solutions12,815,000USDLegacy provider

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.